Over the past 30 years, global obesity rates have doubled, and 500 million people across the globe are currently labeled as obese.
According to Bank of America Merrill Lynch strategist Sarbjit Nahal, roughly half of the global population could be obese by 2030.
In June, Nahal and his team published a massive 141-page report titled Globesity – The Global Fight Against Obesity.
The report includes their "Global Fighting Obesity Exposure" stock list, which consists of over 50 companies making money on the war against obesity.
We pulled the 11 stocks, which BofA identified as having "High" exposure. We also include BofA analysts' current ratings on the stocks.
Arena Pharmaceuticals
Ticker: ARNA
Rating: Underperform
Arena fights obesity through its obesity drug lorcaserin. This drug reduces appetite or food consumption, and has recently been approved by the FDA.
Source: Bank of America Merrill Lynch
Novo Nordisk
Ticker: NOVO (Denmark)
Rating: Buy
Novo Nordisk is a world leader in insulin and diabetes care. The company's drug, Victoza, has three key market opportunities in obesity. Obese diabetics, obese pre-diabetes, and obese with other co-morbities.
Source: Bank of America Merrill Lynch
Orexigen Therapeutics
Ticker: OREX
Rating: Buy
Orexigen fights obesity through its drug Contrave. Trial runs for the drug are now set, and the company has worked with several healthcare systems to accelerate the enrollment rate of the trial. Orexigen has also announced a partnership to develop an exercise program that allows patients to set goals and track progress.
Source: Bank of America Merrill Lynch
See the rest of the story at Business Insider
Please follow Money Game on Twitter and Facebook.